Light and shadows of a new technique: is photon total-skin irradiation using helical IMRT feasible, less complex and as toxic as the electrons one?

Michela Buglione1*, Luigi Spiazzi2, Mauro Urpis1, Liliana Baushi1, Rossella Avitabile2, Nadia Pasinetti1, Paolo Borghetti1, Luca Triggiani1, Sara Pedretti1, Federica Saiani2, Alfredo Fiume2, Diana Greco1, Stefano Ciccarelli1, Alessia Polonini2, Renzo Moretti2 and Stefano Maria Magrini1

Abstract

Background: Radiotherapy is one of the standard treatments for cutaneous lymphoma and Total Skin Electrons Beam Irradiation (TSEBI) is generally used to treat diffuse cutaneous lymphoma and some cases of localized disease. Helical IMRT (HI) allows to treat complex target with optimal dose distribution and organ at risk sparing, so helical tomotherapy has been proposed as alternative technique to TSEBI but only one preliminary report has been published.

Methods: Three patients treated (from May 2013 to December 2014) with Helical IMRT, with a total dose between 24 and 30 Gy, were retrospectively evaluated. Data about dosimetric features, response and acute toxicity were registered and analyzed.

Planned target coverage was compared with daily in vivo measures and dose calculation based on volumetric images used for set up evaluation as well.

Results: The patients had a mean measured surface fraction dose ranging from 1.54 Gy up to 2.0 Gy. A planned target dose ranging from 85 to 120% of prescription doses was obtained. All doses to Organs At Risk were within the required constraints. Particular attention was posed on “whole bone marrow” planned $V_{10Gy}$, $V_{12Gy}$ and $V_{20Gy}$ values, ranging respectively between 23 and 43%, 20.1 and 38% and 9.8 and 24%. A comparison with the theoretical homologous values obtained with TSEBI has shown much lower values with TSEBI. Even if treatment was given in sequence to the skin of the upper and lower hemi-body, all the patients had anaemia, requiring blood transfusions, leukopenia and thrombocytopenia.

Conclusion: Based on our limited results TSEBI should still be considered the standard method to treat total skin because of its pattern of acute and late toxicities and the dose distribution. In this particular case the better target coverage obtained with HI can be paid in terms of worse toxicity. Helical IMRT can instead be considered optimal in treating large, convex, cutaneous areas where it is difficult to use multiple electrons fields in relation with the clinical results and the limited and reversible toxicities.

Keywords: Total skin irradiation, Total skin electrons beam irradiation - TSEBI, Photons, Radiotherapy, Bone marrow, Primary cutaneous lymphoma (PCL), Toxicity

* Correspondence: michela.buglione@unibs.it
1Radiation Oncology Department, University and Spedali Civili Hospital – Brescia, P.le Spedali Civili 1 –, 25123 Brescia, Italy
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Primary cutaneous lymphomas (PCL) are a group of heterogeneous diseases with a typical skin involvement and generally without systemic signs or symptoms, besides that the final stages of Mycosis Fungoides (MF) and Sézary Syndrome (SS). MF/SS can be classified, according to TNM classification, into four clinical stages depending on extension of skin involvement (in percentage of body surface), lymph node metastases, visceral involvement or presence of Sézary cells in blood [1]. Age, type and disease extension, visceral metastases, increased LDH at diagnosis are recognized as prognostic factors [1–3].

Radiotherapy (RT) for PCL has been used in different clinical settings. In patients with solitary nodules of MF, or localized skin B/T disease, RT is the treatment of choice. The treatment of advanced-stage MF-SS is more complex and the final objective is to maintain clinical remission or stabilization of disease, improving quality of life.

Many studies report the efficacy of RT in patients featuring a set of localized lesions (up to three or four lesions covering less than 5% of the body). Routinely, these lesions are treated with a 6–9 MeV single direct electron beam, using a bolus to increase the dose to the cutaneous surface up to 95%. The standard prescribed dose varies from 30.6–36.0 Gy at 1.8–2.0 Gy per fraction. Recurrence rate is about 30% while 92% of patients obtain complete response [4–7].

Low dose large electron fields to treat the entire skin (Total Skin Electron Beam Irradiation, TSEBI) are used for advanced MF allowing a generalized and superficial treatment. [8, 9]. With the already known different standard techniques [10–13], however, it is extremely difficult to obtain a uniform dose distribution, considering the irregular shape of the human body surface [14].

Modern RT techniques have a goal not only to improve cancer cure rate, but also to reduce the treatment related adverse effects. Modern RT techniques have a proven capability to create highly conformal dose distributions, allowing the physicians to escalate the dose within the target volume and to spare adjacent organs at risk (OAR). The clinical use of Tomotherapy® induced radiation oncologists to use this technique to treat cutaneous circumferential localized lesions [15] and to think to use it to perform total skin irradiation. A preliminary report about the use of HI for total skin photon beam cutaneous irradiation has been already published [16]. We report a retrospective analysis on clinical/dosimetric data of three patients with diffuse cutaneous lymphoma treated with HI.

Methods

From May 2013 to December 2014 three patients were treated with total skin photon radiotherapy. The first (#1) had MF (stage IVA1; T4N0M0); the second (#2) had diffuse cutaneous and systemic localizations of cutaneous T cell lymphoma; the third (#3) had a diagnosis of Granulomatous MF (stage II) (Table 1). After receiving adequate information about the technique and the possible acute and late effect of the treatment, all the patients accepted it and signed the informed consent.

| Table 1 Patient’s features, RT prescriptions and response |
|----------------------------------------------------------|
| **Diagnosis** | **Patient #1** (female) | **Patient #2** (male) | **Patient #3** (male) |
| **Previous treatments** | MF (stage IVA1; T4N0M0) with erythrodermic disease, chemotherapy and UVB-PUVA, but never treated with radiotherapy | Diffuse cutaneous and systemic localizations of cutaneous T cell lymphoma, different types of cutaneous therapies (PLVA), chemotherapy and localized RT, and finally proposed for palliative total-skin irradiation | Previously untreated |
| **Prescribed dose** | 27.0 GY/1.8 GY/fr (upper body) | 28.8 GY/1.8 GY/fr (upper body) | 30.4 GY/1.9 GY/fr (upper body) |
| **Compensative electrons boost on "under-dosed" regions** | One field electron boost (upper back) after the end of the photon treatment | 4 electron field boosts (right arm, left arm, inguinal, right foot dorsum) | 9 electron field boosts (right and left forearm, right and left arm, right back, left back, internal right thigh) |
| **Response to RT and duration** | Short complete remission (6 months) | Short complete remission (6 months) | Complete remission (4 years) |
the entire body surface with a thickness of 5 mm. GTV plus 5 mm was included in CTV. PTV was defined as CTV plus 5 mm geometrical external margin and 7 mm internal margin. (Fig. 1). PTV was divided in PTV eval (the intersection of PTV and the patient body contour) and OPTV, (PTV portion outside body contour).

Optic nerves, lens, eyes, lacrimal glands, cochlea, mandibles, parotids, thyroid, great vessels and heart, lungs, humeral heads, femoral heads, liver, stomach, intestinal cavity, spleen, kidneys, bladder, breast, rectum and uterus (for #1), testicles, penis and corpora cavernosa (for #2 and #3) were defined as OAR. Bone marrow was defined as the tissue within cortical bone of sternum, ribs, cranial, pelvic and long bones [17, 18].

The defined IGRT protocol included two daily MVCT, one at the beginning and one at the end of the volume in order to better evaluate the patient’s set-up along the all volume [25]. The median differences between the two MVCT revealed movements, were applied for the treatment.

To compare bone marrow dose resulting from the use of different techniques (electrons versus photons), and even if with the limits of the absence of a TPS calculating the real electrons dose distribution, a theoretical planned DVH was retrospectively obtained considering the percentage depth dose (PDD) applied to patients treated with electrons (30.0 Gy; 86% at 7 mm). With the same intent, a bone marrow volume included in the superficial body layer was created. It was obtained with an automatic symmetrical contraction of the contoured external body volume of different extent (2 to 28 mm). Considering a dose prescription for TSEBI (28.8 Gy in 16 fraction), estimated DVH points were calculated, combining bone marrow volume included in the superficial layers and the measured dose curve in the conditions of the TSEBI setup. (Fig. 2).

Clinical dose prescription
The prescribed doses were different for the three patients (Table 1) but always within the therapeutic range. Considering the 160 cm maximal target length in Tomotherapy® and to allow partial bone marrow recovery, the treatment was always delivered in two consecutive sessions of 13–16 fractions each. Upper body and lower body were treated
posing the junction in a stable section of the body depending on each patient anatomy and set-up. The treatments were delivered 5 days a week for all the patients and all the sessions. All the patients had electron boosts to compensate under dosages (Table 1) or to treat macroscopic disease. In order to avoid over/under dosage in the treatments junctions, both the upper and the lower regions had two steps gradient regions, 5 cm each.

Physical features of the treatment

The treatments were delivered with Helical IMRT (Tomotherapy®) with MVCT for set-up verification. All the plans were calculated with a 5 cm collimator. To reach a more homogeneous dose distribution, both PTV_eval and OPTV were divided in multiple sub-volumes during the optimization process. The OPTVs were included separately in the optimization to have a planned photon fluency that could expand beyond the planning CT body and treat efficiently the patients’ skin.

To reach adequate lungs and lens DVH values, the respective PRV were blocked during the optimization process. Other inner ad hoc volumes, obtained as a contraction of 2 cm of the body contours, were created and completely blocked in the optimization process to avoid internal organ irradiation. Eye Lens with 6 mm margin were, as well, completely blocked. All plans were elaborated with Helical Irradiation and computed with calculation grid fine. [19]. The plans characteristics of the different patients are reported in Table 2.

All plans underwent three different kinds of Quality Assurance (QA) procedures: a) multiple standard pre-treatment dosimetric QA with measurements of the dose delivered to two phantoms (A1SL Exradin -Standard Imaging ionization chamber- in a cheese phantom; PTW Octavius chambers array for planar doses); b) daily delivered dose calculations based on MVCTs, co-registered with the planning CT (DODA, Dose of the day); c) in vivo dosimetry performed with Gafchromic films (EBT3®).

The Gaf-chromic films were positioned on the patients’ skin, in points considered at higher risk for dose distribution alterations. Lower and upper posterior aspect of torso, lateral aspect of the right and left arm, forehead, cheek, nape, scapula, sternum, right and left thigh, right and left hand dorsum, right and left foot dorsum, abdomen, pubic region, skin over fibula and medial/lateral aspect of right and left tibia were considered.

The exact positions of Gaf dosimeters were recorded to estimate, from daily dose distribution, the expected doses to match the result with. The films were handled according to AAPM TG-55 report [20].

Response assessment

Patients were evaluated weekly during the treatment, one time 1 month after the end of the treatment and then every 3 months. Complete response was defined as complete disappearance of cutaneous lesions. Disease recurrence was defined in a multidisciplinary team (radiation oncologist, dermatologist and hematologist).
Toxicity evaluation
Acute toxicity was defined as cutaneous and haematological damage appearing during the treatment and within 3 months after the end of radiotherapy. Adverse events occurring more than 3 months after the end of radiotherapy were defined as late toxicity. All the toxic events were defined with the CTCAE.4 scale. The possible relationship between clinical toxicity and dosimetric parameters was evaluated. The follow up was continued for all the patients (every 3 months) after the end of the treatment to evaluate late toxicity and outcomes.

Statistical analysis
Results were compared with the \( z \)-test when a sample of data was compared with a reference value. t-Student test was used for paired data when two samples of data were compared. The differences were considered statistically significant if \( p < 0.01 \) to account for the high number of tests performed.

Results
Target dose
Deviation of planning median dose from the prescribed one were within 3% and therefore considered acceptable.

The planned doses per fraction to the target were compared with the DODA calculated for each fraction. Dose-volume points did not result significantly different, but in the few cases where the average DODAs were significantly higher than the provisional ones (eg. for patient #2 average D2% of the “lower volume” 2.1 Gy (SD 0.05 Gy) vs 2.1 Gy; average D95% 1.1 Gy (SD 0.06 Gy) vs 0.9 Gy; average D2% of the “upper volume” 2.3 Gy (SD 0.03 Gy) vs 2.2 Gy). Differences between the in vivo measures and DODA mean values for the different regions of the three patients were statistically different only in selected sites (upper back, right hand and foot dorsum for patient #1; the back and forearms for patient #2; the back, shoulders, harms and forearms for patient #3). Table 3 reports the target DVH outcomes for the patients obtained by means of Tomotherapy treatment planning. Cumulative plans are considered for each patient’s session. The results are calculated for the PTV_e-val contours. The data show that the best target coverage was obtained in patient #3.

Organs at risk dose
Doses to the different OARs were within the safe limits. Higher mean doses were evident in superficial organs as lacrimal glands in pat #3 (16.7 Gy) parotids in all patients (range 18.1–20.9 Gy), thyroid (range 7.5–17.5 Gy), testicles respectively 27.0 Gy and 18.7 Gy for pat #2 and #3. The doses of all defined OAR are reported in Table 4.

Some structures had a large mean dose variation between the three patients. Lacrimal glands, parotids and thyroid mean variation was due to patient

Table 2 Tomotherapy® plan characteristics

| Pat | Treatment session | Plan | Duration (min) | N. rotations | N. fractions | Number of PTV sub-volumes used in optimization | Number of region at risk used in optimization |
|-----|------------------|------|---------------|-------------|-------------|---------------------------------|--------------------------------|
| #1  | Upper Hemibody   | #1   | 22.6          | 45.3        | 3           | 56                              | 33                              |
|     |                  | #1   | 22.6          | 43.7        | 12          | 56                              | 25                              |
|     | Lower Hemibody   | #1   | 23.6          | 19          | 10          | 14                              | 14                              |
|     |                  | #1   | 23.6          | 19          | 3           | 14                              | 14                              |
| #2  | Upper Hemibody   | #2   | 27.1          | 56          | 8           | 59                              | 27                              |
|     |                  | #2   | 28.9          | 56          | 8           | 68                              | 28                              |
|     | Lower Hemibody   | #2   | 40.0          | 50.1        | 3           | 45                              | 35                              |
|     |                  | #2   | 40.0          | 50.1        | 13          | 46                              | 34                              |
| #3  | Upper Hemibody   | #3   | 27.2          | 52.7        | 3           | 61                              | 45                              |
|     |                  | #3   | 27.2          | 52.7        | 13          | 74                              | 56                              |
| Lower Hemibody | #3   | 29.4          | 83.9        | 15          | 71                              | 42                              |

Table 3 Target dose volume points

| Treatment session | DVH point | Patient #1 | Patient #2 | Patient #3 |
|-------------------|-----------|------------|------------|------------|
| Upper hemi body:  | D (10 ml) | 30.8       | 34.1       | 35.7       |
| #1: 27/1.8 Gy     | D (2%)    | 30.0       | 33.1       | 34.9       |
| #2: 28/1.8 Gy     | D (50%)   | 26.4       | 28.5       | 30.9       |
| #3: 28/1.8 Gy     | D (90%)   | 22.4       | 22.2       | 23.8       |
| #3: 27/1.8 Gy     | D (95%)   | 19.4       | 19.7       | 19.8       |
| Lower hemi body:  | D (10 ml) | 29.6       | 33.6       | 35.3       |
| #1: 26/2 Gy      | D (2%)    | 28.9       | 33.0       | 34.5       |
| #2: 28/1.8 Gy     | D (50%)   | 25.7       | 28.5       | 30.9       |
| #3: 27/1.8 Gy     | D (90%)   | 23.1       | 19.7*      | 28.5       |
| #3: 29/1.8 Gy     | D (95%)   | 21.7       | 14.2*      | 27.5       |

*electron field boost performed in the under dosage regions
anatomy, while bladder, rectum and bowel cavity mean
doses where affected both by patient anatomy and by the
choice of upper and lower plans overlapping regions.

The differences between the DODA to the single or-
gans and the planned ones were not statistically signifi-
cant. The mean doses to the internal OARs are all < 1.0 Gy per fraction; the confidence limit of organs
DODAs mean doses are shown in Table 4. Organs gen-
erally received lower doses than the planned ones.

Bone marrow dose
The median and mean whole bone marrow cumulative
doses for the entire treatment (upper plus lower plan)
were 4.0 Gy and 8.5 Gy for patient #1; 4.5 Gy and
10.1 Gy for patient #2 and 6.5 Gy and 12.0 Gy for pa-
tient #3. These average cumulative doses were given in
two consecutive sessions. Therefore, while the fraction
of the bone marrow included in the upper part of the
body is receiving a dose, the lower part of the body (and
the corresponding bone marrow fraction) is not; the re-
verse is also true.

With TSEBI, the provisional values of bone marrow
$V_{10\text{Gy}}$, $V_{12\text{Gy}}$ and $V_{20\text{Gy}}$ were lower than those obtained
with photons. In particular they were respectively 17%,
14.5%, 9.6% for patient #1; 14.5%, 13.7% and 9.4% for pa-
tient #2, 6.6%, 5.1% and 2.8% for patients #3. Median
bone marrow dose for TSEBI would have been 0.4 Gy,
0.35 Gy and 0.35 Gy respectively for patient #1, #2 and
#3; the average bone marrow dose would have been
3.6 Gy, 3.3 Gy and 1.3 Gy, respectively. (Fig. 6).

Acute toxicity
Non-haematological toxicity
All patients had transient G2–3 skin toxicity with ery-
them and epitheliolysis, especially in sites with non-
homogeneous dose distribution (axillary, inguinal re-
gions and fingers). All patients experimented alopecia,
nails alterations and oral mucositis (G2–3). All patients
had plantar feet pain during 2 months after the end of
treatment. All the symptoms were controlled with specific
supportive care.

Haematological toxicity
All patients experienced anaemia requiring blood
support and neutropenia requiring growth factors. Thrombocytopenia was evident in two patients

| Table 4 | Previsional OAR’s mean doses and DODA average mean doses CLs (99.7% 3σ) |
|---------|--------------------------------------------------|
| Organs  | Plans total mean dose (Gy)                      | DODAs mean doses CL – 3σ(Gy) |
|         | Pat #1 | Pat #2 | Pat #3 | Pat #1 | Pat #2 | Pat #3 |
| Bowel (abdominal cavity) | 1.1 | 10.9 | 3.9 | 0.89–0.93 | 8.7–9.0 | 4.6–4.8 |
| Brain   | 4.5   | 3.2   | 4.6   | 4.3–4.5 | 3.1–3.6 | 4.5–4.6 |
| Cord    | 3.1   | 6.7   | 6.1   | 3.2–3.6 | 6.69–6.73 | 6.1–6.9 |
| Oesophagus | 3.6   | 8.1   | 5.9   | 3.6–3.7 | 7.9–8.0 | 5.7–5.8 |
| Heart   | 3.3   | 4.6   | 5.4   | 3.26–3.30 | 4.55–4.59 | 5.4–5.5 |
| Lacrimal glands | 3.1   | 3.3   | 16.7  | 3.9–4.6 | 3.7–3.8 | 13.3–13.6 |
| Lens    | 1.9   | 2.2   | 5.9   | 2.1–2.7 | 2.2–2.4 | 6.2–6.5 |
| Liver   | 2.4   | 4.3   | 4.3   | 2.3–2.4 | 4.2–4.3 | 4.4–4.5 |
| Lungs   | 2.3   | 3.5   | 3.1   | 2.17–2.20 | 3.36–3.38 | 3.30–3.32 |
| Parotids | 20.9  | 19.5  | 18.1  | 19.5–20.3 | 16.7–18.2 | 18.5–18.7 |
| Thyroid | 17.5  | 14.4  | 7.5   | 14.1–14.7 | 14.5–14.7 | 6.9–7.0 |
| Oral cavity | 5.5   | 2.7   | 2.5   | 5.2–5.5 | 2.69–2.72 | 2.36–2.42 |
| Spleen  | 2.7   | 4.6   | 9.9   | 2.5–2.6 | 4.3–4.6 | 94–9.6 |
| Kidneys | 3.1   | 3.8   | 3.3   | 3.0–3.2 | 3.56–3.58 | 3.34–3.39 |
| Stomach | 2.4   | 2.1   | 2.1   | 1.6–1.6 | 1.96–1.98 | 2.07–2.11 |
| Bladder | 11.0  | 2.6   | 1.4   | 9.1–9.4 | 2.30–2.34 | 1.31–1.31 |
| Rectum  | 15.9  | 4.8   | 1.6   | 13.6–13.8 | 4.6–4.8 | 1.44–1.46 |
| Uterus  | 13.8  | /     | /     | 10.8–11.3 | /     | /     |
| Testicles | /     | 27.0  | 18.7  | /     | 27.2–28.8 | 19.9–20.2 |
| Penis and corpora cavernosa | /     | 24.0  | 9.9   | /     | 22.3–22.4 | 7.5–8.0 |
and recovered within 6 months after RT. Haematological toxicity has been worse, including prolonged thrombocytopenia, in Patient #3. Patient #1 had G2 anaemia twice, during the lower body and upper body treatment; G3 thrombocytopenia and G2 neutropenia. The haematological toxicity increased during the treatment in parallel with the increase of RT dose to the bone marrow. All the acute toxicities recovered within 2 months after the end of the treatment. Patient #2 had G1 anaemia, G3 neutropenia and G1 thrombocytopenia at the end of both sessions, treated with blood transfusions and growth factors. Anemia, neutropenia and thrombocytopenia were respectively G2, G1 and G3 for Patient #3 at the end of the

**Fig. 3** Bone marrow DVHs, Total, upper session and lower session DVHs patient 1

**Fig. 4** Bone marrow DVHs, Total, upper session and lower session DVHs patient 2
Fig. 5 Bone marrow DVHs, Total, upper session and lower session DVHs patient 3

Fig. 6 Bone marrow DVHs. Solid lines photon beam TSI (planned cumulative doses); dotted lines (TSEBI cumulative doses as derived theoretically from PDD)
treatment. All the acute toxicities but thrombocytopenia (70,000/UL t 3 years after the end of RT) recovered within 2 months after the end of the treatment.

Response
The immediate disease response was good in all the patients. In one patient, treated with radical intent, the response was durable. (Table 1).

Discussion
Large electrons fields perpendicular to the body of the patient, who is standing and rotated in 6 differently angled positions, are used to treat the entire skin, when indicated, according to the most used technique, the Stanford one [21]. The physical distribution of electrons [22] requires the use of fields perpendicular to the surface of the target and do not allow to treat concave or convex volumes with a homogeneous dose. With Total Skin Electron Beam Irradiation (TSEBI) a 2.0 Gy/fraction to the whole skin is delivered in 2 days (three body positions a day), and the patient is treated 5 days a week. No hematological toxicity is generally reported for TSEBI approach, where it is not possible to correct hot and cold regions and to manage them; for this reason, re-planning was an important part of the process. This is clearly an advantage over the standard TSEBI technique approach, where it is not possible to correct for the inhomogeneous dose distribution [21].

OAR dose distribution
The median doses to internal OARs, in the other published report, were 29.3 Gy and 24.7 Gy for the parotid and thyroid gland, respectively; 8.0 Gy for the brain; 5.2 and 6.8 Gy for liver and spleen; 3.8, 2.5 and 2.1 Gy for spinal cord, brain stem and lens, respectively. The authors report also median doses to lungs (4.5/4.7 Gy), heart (3.3 Gy) and kidneys (3.9/4.3 Gy) [16]. In our series, we reported mean organ doses and all the doses received by the OARs were largely within the accepted dose constraints and in line with those reported in the previous experience. As expected, doses to superficial organs were higher than those to the deeper ones, due to the photon characteristic depth curve.

Bone marrow dose
Haematopoietic bone marrow is very radiation sensitive and it can be considered the most important OAR for this treatment because, particularly in districts as cranial bones, ribs and sternum, it is very close to the target (< 1 cm). Up to 30–40% of total bone marrow could be within the first 3 cm of the outer body layer. Bone marrow total dose was carefully analyzed, also in relation with haematological toxicity and it was demonstrated a correlation with bone marrow RT dose.

In patients treated with radio-chemotherapy for cervical cancer, with a median pelvic RT dose of 45.0 Gy (range, 36.0–50.4) and a median point A dose (in patients undergoing intracavitary implants using low-dose-rate brachytherapy) of 85.0 Gy (range, 75.0–87.0), pelvic bone marrow V10Gy values of > 90% are related to higher rates of hematologic G3-G4 toxicities and delays in chemotherapy administration [29]. Similarly, Albuquerque et al.
reports, in patients who received 45.0 Gy with concurrent weekly cisplatin for cervical cancer, a significant increase of Grade 2–3 hematologic toxicity when ≥80% of whole pelvic bone received 20.0 Gy [30, 31]. The RT total body dose used to induce aplasia, conditioning bone marrow transplantation, is 12.0 Gy with a twice a day fractionation regimen (2.0 Gy/fraction) [31, 32].

Chen-Hsi Hsieh et al. identified the bone of the spine (cervical, thoracic, lumbar and sacrum) as haematopoietic bone marrow. Right and left iliac crest, right and left femurs, right and left pelvic bone, ribs and cranial theca, were not included in the bone marrow volume. The median doses reported in their experience ranged between 4 Gy (lumbar spine and sacrum) to 9 Gy (iliac crests), to >12 Gy (femurs and pelvic bones). All these parameters can be used as a reference to evaluate bone marrow dosimetric results for the present series also considering that bone marrow was outlined in its entirety. The planned mean doses were 8.5 Gy for the first patient and, respectively, 10.1 and 12.0 Gy for patients #2 and #3. The average DODAs were slightly but significantly higher for the first lower plan and for the second upper plan, for the first patient and slightly lower for both the upper plans for the third patient. However, the skin of the upper and the lower hemi-body have been treated sequentially, with an interval up to about 3 weeks between the two treatment sessions. Thus, only about half of the bone marrow was directly exposed in each of the two sessions. It could therefore be considered that while part of the marrow is accumulating damage, the other is not (or not to the same extent) or is recovering.

The bone marrow mean and median doses are slightly higher for patient #3, probably in relation with treatment planning optimization. This could be the reason for protracted thrombocytopenia of patient #3, along with the shorter interval between the first and the second session of the treatment (Table 1). In fact, the total mean dose of 12.0 Gy was delivered during the entire treatment (31 fractions) with a mean dose per fraction of 0.4 Gy.

The average bone marrow doses given with photon TSI, even if are much lower than those used as a conditioning regimen in bone marrow transplantation, are sufficient to induce bone marrow toxicity. In fact, this is what happened with low dose TBI used in different trials to obtain bone marrow disease control in follicular lymphomas. [33, 34] The bone marrow dose volume points for a hypothetical TSEBI treatment, with the same dose regimen, would have been significantly lower for all patients. Since this is the main cause of hematological toxicity, it can be considered as a limiting factor for the use of this technique to treat total skin. In fact, one out of only three patients had late thrombocytopenia.

Toxicity

As far as toxicity is concerned, doses to the internal organs (abdominal cavity, kidney, spleen and eyes) are lower than those defined as “constraints” but they are higher than those given using electrons that is less than 0.3 Gy on average to organs located at a depth of more than 3 cm. (Fig. 4).

Although a direct comparison between the toxicity related to HT and TSEBI is not possible, due to the very small number of HT treated cases, data from the literature (6) and from our experience with TSEBI point to a substantial similarity of the skin/nails damage and of the other non-hematologic toxicities induced by the two techniques. Superficial organs as lacrimal glands, thyroid, and lenses receive similar or lower doses than those given with TSEBI, and the resulting toxicity does not seem to be substantially different.

However, TSEBI hematologic toxicity is scarce, whereas all our patients had different degrees (G2–3) of hematologic toxicity (even if patient #1 marrow doses were close to those expected with TSEBI).

Conclusions

Based on previous published experiences of the use of Helical IMRT to treat large and complex superficial volumes, this is the second report on total skin treatments with photons performed with this technique.

As expected, dose homogeneity has been better than with TSEBI and a durable remission has been obtained in the unique patients treated with radical intent.

Even if a relative increase in bone marrow toxicity was expected, its extent was unexpected, considering also the split course nature of the treatment.

Therefore, according to our results, TSEBI should still be considered the standard method to treat total skin because of its pattern of acute and late toxicities and further use of helical IMRT for this treatment discouraged: the better target coverage obtained with HI is not clearly related to better clinical response and can possibly induce worse toxicity.

On the other hand, considering the data published, the clinical results and the limited and reversible toxicities in treating volumes smaller than total skin, Helical IMRT can be considered optimal in treating large, convex, cutaneous areas where it is difficult to use multiple electrons fields.

Abbreviations

CR: Complete response; CTV: Clinical target volume; DODA: Dose of the Day. Calculation of daily delivered dose based on the verification MVCT; DvH: Dose volume histogram; Dy%: Dose at least received from y% of volume (y is a number between 0 and 100); GTV: Gross tumor volume; HI: Helical IMRT; IGRF: Image guided radiation therapy; IMRT: Intensity modulated Radiation Therapy; MF: Micosis Fungoides; MVCT: Megavoltage computed tomography; OAR: Organs at risk; OPTV: Outside the body surface PTV; PCL: Primary cutaneous lymphomas; PD: Progressive disease; PR: Partial...
response; PRV: Planning organ at Risk Volume; PTV: Planning target volume; QA: Quality Assurance; RT: Radiotherapy; SS: Sézary Syndrome; TSEB: Total skin electron beams irradiation; \( V_{\text{X Gy}} \): Percentage of volume receiving at least \( X \) Gy (\( X \) is a number)

### Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### Authors' contributions
MB: treated the patients, collected and analysed the data; wrote and revised the paper. LS: performed the treatment planning, collected and analysed the data; wrote and revised the paper. MU: treated the patients and collected the data. LB: treated the patients and collected the data. RA: performed the treatment planning. NP: treated the patients. PB: treated the patients. LT: treated patients and collected the data. SP: treated the patients. FS: performed the treatment planning. AF: performed the treatment planning. DG: treated the patients. SC: treated the patients. AP: helped in the treatment planning. SVM: revised the paper. All authors read and approved the final manuscript.

### Ethics approval and consent to participate
The project and the paper have been both evaluated by the Ethical Committee of the ASST-Spedali Civili. Brescia.

### Consent for publication
The subjects consented the publication using the Institutional Consent. Individual data requiring specific consent are not included in the paper.

### Competing interests
The authors declare that they have no competing interests.

### Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Author details
1.Radiation Oncology Department, University and Spedali Civili Hospital – Brescia, P.le Spedali Civili 1 –, 25123 Brescia, Italy. 2.Medical Physics, Spedali Civili Hospital – Brescia, P.le Spedali Civili 1 –, 25123 Brescia, Italy.

### Received: 9 June 2018 Accepted: 14 August 2018

### Published online: 29 August 2018

### References
1. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization for Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713–22.
2. Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008;112:3082–7.
3. Yen A, McMichael A, Kilkenny M, et al. Mycosis fungoides: an Australian experience. Australas J Dermatol. 1997;38(Suppl):S86–90.
4. Hopper R. Mycosis Fungoides: radiation therapy. Dermatol Ther. 2003;16:347–54.
5. Cotter GW, Baglan RJ, Wasserman TH, et al. Palliative radiation treatment of cutaneous mycosis Fungoides as a dose response. Int J Radiat Oncol Biol Phys. 1983;9:1477–80.
6. Elsayad K, Krichaj W, Moustakis C, Scibolao S, Reinart G, Haverkamp U, Willich N, Weishaupt C, Stadler R, Sundekötter C, Eich HT. Total skin Electron beam for primary cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015;93(5):1077–86. https://doi.org/10.1016/j.ijrobp.2015.08.041.
7. Pedretti S, Urpis M, Leali C, Borgiotti P, Baushi L, Sala R, Tucci A, Greco D, Pasinetti N, Triggiani L, Rossì G, Catavata-Pinton P, Magrini SM, Buglione M. Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines. Tumori. 2017; https://doi.org/10.5301/tum.5000606.
8. Gouyon E, Truc G, Pétrela T, Maignon P, Jeudy G, Collot E, Galloët C, Dalac-Rat S. Total skin electron beam for early-stage mycosis fungoides: immediate results and long-term follow-up in 68 patients. Ann Dermatol Venereol. 2009;136(3): 249–55. https://doi.org/10.1016/j.annder.2008.11.017.

9. Gitterl SL, Fung MA efficacy of treatments for mycosis fungoides and Sézary syndrome: nationwide survey responses. Dermatol Online J. 2005;11(3).
10. Karmack C. 1987. Total skin electron therapy: technique and dosimetry. Report no. 23.
11. Piotrowski T, Malecki J. The rotary dual technique for total skin irradiation in the treatment of mycosis fungoides - a description of applied method. Rep Pract Oncol Radiother. 2006;11(9):29–37.
12. Hensley F, Major G, Edel C, Hauswald H, Bischof M. Technical and dosimetric aspects of the total skin electron beam technique implemented at Heidelberg University Hospital. Rep Pract Oncol Radiother. 2014;11:135–43.
13. Podgorsak EB, Pia C, Pla M, et al. Physical aspects of a rotational total skin electron irradiation. Med Phys. 1983;10:159–68.
14. Gamble LM, Farrell TJ, Jones GW, Hayward JE. Two-dimensional mapping of underdosed areas using radiochromic film for patients undergoing total skin electron beam radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 62(3):920–4.
15. Mazzeo E, Rubino L, Buglione M, Antognoni P, Magrini SM, Bertoni F, Parmiggiani M, Barbieri P, Bertoni F. The current management of mycosis Fungoides and Sézary syndrome and the role of radiotherapy: principles and indications. Rep Pract Oncol Radiother. 2013;19(2):77–91. Review.
16. Hsieh CH, Shueng PW, Lin SC, Tien HJ, Shiau AC, Chou YH, Wu MH, Wang YJ, Chen CK, Chen YJ. Helical irradiation of the total skin wh it dose painting to replace total skin electron beam therapy for therapy-refactory cutaneous CD4+ T-cell lymphoma. Biomed Res Int; 2013. https://doi.org/10.1155/2013/ 7179596.
17. Morrison SJ, ScaIdden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505(7483):327–34. https://doi.org/10.1038/nature12984.
18. Clarke B. Normal Bone Anatomy and Physiology. Clin J Am Soc Nephrol. 2008;3(Suppl 3):S131–9. https://doi.org/10.2215/CJN.04152006.
19. Piotrowski T, Czajka E, Bak B, Kazmierska J, Storoka M, Ryczkowski A, Adamczyk M, Jodda A. Tomotherapy: implications on daily workload and scheduling patients based on three years’ institutional experience. Technol Cancer Res Treat. 2014;13:233–42.
20. Niromand-rad A, Blackwell CR, Coursey BM, Gall KP, Galvin JM, MacLaughlin WL, Meigooni AS, Ravinder N, Rodgers JE, Soares CG. Radiochromic film dosimetry: recommendations of AAPM radiation therapy committee task group 55. Med Phys. 1998;25(11):2093–115.
21. Hoppe RT, Fuku Z, Bagshaw MA. The rationale for curative radiotherapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 1972;7:843–51.
22. Gallhauser R, Landberg T, Chavaudra J, Dobbis J, Gupta N, Hanks G, Horiot J-C, Johansson K-A, Möller T, et al. Physical characteristics of electron beams. Journal of the ICRU. 2004;4:1. https://doi.org/10.1093/jicru/ind009. Oxford University Press
23. Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron irradiation in the management of mycosis fungoides consensus of the European organization to the research and treatment of cancer (EORTC) cutaneous lymphoma project group. J Am Acad Dermatol. 2002;47:364–70.
24. Ostherrme C, Janich M, Hübsch P, Gerlach R, Vordermark D. The treatment of extensive scalp lesions using cobulan and non-cobulan photon IMRT: a single institution experience. Radiat Oncol. 2014;9:82.
25. Conroy R, Zeverino M, Vagge S, Agostinelli S, Bara S, et al. Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant. Radiother Oncol. 2011;98:382–6.
26. Han C, Schultheiss TE, Wong JYC. VMAT in total marrow irradiation Dosimetric study of volumetric modulated arc therapy fields for total marrow irradiation. Radiother Oncol. 2012;102:315–20.
27. Wong JYC, Rosental J, Liu A, Schultheiss T, et al. Image guided Total marrow irradiation using helical Tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys. 2009;73(1):1273–9.
28. Takahashi Y, Stefano Vagge MD, Agostinelli S, Han E, Matulewicz L, et al. Multi-institutional Feasibility Study of a Fast Patient Localization Method in Total Marrow Irradiation With Helical Tomotherapy: A Global Health Initiative by the International Consortium of Total Marrow Irradiation. Int J Radiol Oncol Biol Phys. 2015;91(1):30–8.
29. Mell LK, Kochanski JD, Roeseke JC, Haslam JJ, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;65:1356–65.
30. Albuquerque K, Giangreco D, Morrison C, Siddiqui M, et al. Radiation-related predictors of hematologic toxicity after concurrent chemoradiation for cervical cancer and implications for bone marrow-sparing pelvic IMRT. Int J Radiat Oncol Biol Phys. 2011;79:1043–7.
31. Aristei C, Santucci A, Corvo R, Gardani G, et al. In hematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study. Bone Marrow Transplantation. 2013;48:908–14.
32. Hank B, O’Reilly R, Cunningham I, Kernan N, Yaholom J, Brochstein J, et al. Total body irradiation for bone marrow transplantation: the Memorial Sloan-Kettering Cancer Center experience. Radiother Oncol. 1990;18(Suppl 1):68–81.
33. Richaud PM, Soubeyran P, Eghbali H, et al. Place of low-dose total body irradiation in the treatment of localized follicular non-Hodgkin’s lymphoma: results of a pilot study. Int J Radiat Oncol Biol Phys. 1998;40(2):387–90.
34. Meerwaldt JH, Carde P, Burgers JM, et al. Low-dose total body irradiation versus combination chemotherapy for lymphomas with follicular growth pattern. Int J Radiat Oncol Biol Phys. 1991;21(5):1167–72.